Biohaven Ltd.
NYSE:BHVNBiotechnology
-$0.22 today
- Market cap
- $1.95B
- Beta
- 3.31
- P/E (TTM)
- -3.1
- EPS (TTM)
- -$4.39
Volume 2.32M
Average 2.47M
BHVN Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Biohaven Ltd.NYSE: BHVN
Operating Expenses · Q2 FY2026 · quarter ended Jun 2026
Operating expenses declines year over year
Q2 FY2026 operating expenses of $124.9M fell 41.0% year over year, behind the -29.4% change in trailing-twelve-month operating expenses. Sequentially, it fell 4.2% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.
Context
- Operating expenses increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -41.0% toward the trailing-twelve-month pace of -29.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 741.24M USD
- Year-over-year change
- -16.3%
- 4-year CAGR
- +35.7%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 741.24M | -16.3% |
| FY2024 | 2024-12-31 | 885.11M | +103.0% |
| FY2023 | 2023-12-31 | 436.05M | -23.2% |
| FY2022 | 2022-12-31 | 567.93M | +159.4% |
| FY2021 | 2021-12-31 | 218.9M | — |
Operating Expenses vs competitors
How BHVN compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -29.4% is the lowest of 11, against a peer median of +41.3%.
- Over three fiscal years its annual growth of +9.3% compares with a peer median of +26.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $565.38M USD | -29.4% | +9.3% | — | |
| LTM Jun 2026 | $415.76M USD | +76.1% | +50.9% | — | |
| LTM Mar 2026 | $410.51M USD | +8.6% | +21.4% | 106.4% | |
| LTM Sep 2026 | $333.75M USD | +278.1% | +101.5% | 297994.6% | |
| LTM Mar 2026 | $319.32M USD | +163.2% | +148.0% | — | |
| LTM Mar 2026 | $319.11M USD | -10.9% | -0.7% | 482.8% | |
| LTM Sep 2026 | $299.94M USD | +54.6% | +80.8% | — | |
| LTM Sep 2026 | $253.48M USD | -14.5% | +9.2% | 373.5% | |
| LTM Mar 2026 | $220.98M USD | +9.0% | +8.0% | 70.2% | |
| LTM Sep 2026 | €193.36M EUR | +125.2% | +25.1% | — | |
| LTM Mar 2026 | $98.47M USD | +28.0% | +28.8% | — | |
| Peer median (excluding BHVN) | — | +41.3% | +26.9% | 373.5% | |
Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 4.14M |
| Gross Profit | 0 | 0 | 0 | 0 | (4.14M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 181.49M | 437.07M | 373.28M | 795.87M | 635.07M |
| Selling, General & Admin | 37.41M | 130.86M | 62.77M | 89.24M | 106.17M |
| Operating Expenses | 218.9M | 567.93M | 436.05M | 885.11M | 741.24M |
| Depreciation & Amortization | 1.39M | 1.39M | 6.91M | 7.86M | 9.92M |
| EBITDA | (211.04M) | (568.46M) | (402.64M) | (837.83M) | (727.46M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (218.9M) | (567.93M) | (436.05M) | (885.11M) | (745.38M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 17.73M | 21.33M | 14.59M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 6.47M | (1.91M) | 26.5M | 39.42M | 8M |
| Income Before Tax | (212.43M) | (569.84M) | (409.55M) | (845.69M) | (737.38M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 1.37M | 438K | (1.38M) | 735K | 1.44M |
| Net Income | (213.8M) | (570.28M) | (408.17M) | (846.42M) | (738.82M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| EPS (Diluted) | (5.97) | (12.75) | (5.73) | (9.28) | (6.86) |
| Weighted Avg Shares | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
| Weighted Avg Shares (Diluted) | 35.82M | 44.74M | 71.2M | 91.23M | 107.62M |
Biohaven Ltd.
NYSE:BHVN
Intrinsic Alpha fair value
Locked
Current Price
$12.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.